Given the interest in HCV in these parts, I’m surprised no one has commented on the comments in #msg-50187183. Is MRK pulling a fast one on the investment community by touting a Boceprevir NDA submission in 2010 while internally planning for an FDA decision to be delayed until 2012 or 2013? (This is a serious question, not a rhetorical one.)
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.